A P Dei Tos
Overview
Explore the profile of A P Dei Tos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
3805
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vanzulli A, Vigorito R, Buonomenna C, Palmerini E, Quagliuolo V, Broto J, et al.
ESMO Open
. 2025 Mar;
10(3):104299.
PMID: 40056850
Background: We report the results of the pre-planned secondary analysis of radiologic responses (RRs) of ISG-STS 1001, a randomized trial comparing anthracycline + ifosfamide (AI) versus histology-tailored (HT) neoadjuvant chemotherapy...
2.
Miglietta F, Collesei A, Vernieri C, Giarratano T, Giorgi C, Girardi F, et al.
ESMO Open
. 2024 Dec;
10(1):104087.
PMID: 39705838
Background: HER2-low expression has gained clinical relevance in breast cancer (BC) due to the availability of anti-HER2 antibody-drug conjugates for patients with HER2-low metastatic BC. The well-reported instability of HER2-low...
3.
Giani C, Denu R, Ljevar S, Gronchi A, Napolitano A, Rosenbaum E, et al.
ESMO Open
. 2024 Sep;
9(9):103689.
PMID: 39265219
Background: To present findings from a retrospective study conducted by the Ultra-Rare Sarcoma Working Group on metastatic low-grade fibromyxoid sarcoma (LGFMS), sclerosing epithelioid fibrosarcoma (SEF), and hybrid (H)-LGFMS/SEF across 28...
4.
Pantano F, Simonetti S, Iuliani M, Guillen M, Cuevas C, Aviles P, et al.
Oncogene
. 2024 Aug;
43(40):2986-2994.
PMID: 39198616
Trabectedin, approved for the treatment of soft tissue sarcoma (STS), interferes with cell division and genetic transcription processes. Due to its strong anti-tumor activity in only certain histotypes, several studies...
5.
Fabbroni C, Grignani G, Vincenzi B, Fumagalli E, De Pas T, Mazzocca A, et al.
ESMO Open
. 2024 Aug;
9(8):103667.
PMID: 39121815
Background: This is a multicentre, single-arm, phase II study aimed at further exploring the activity of trabectedin as second-/further-line treatment in retroperitoneal leiomyosarcoma (LMS) and well-differentiated/dedifferentiated liposarcoma (LPS). Materials And...
6.
Blay J, Hindi N, Bollard J, Aguiar Jr S, Angel M, Araya B, et al.
Cancer Treat Rev
. 2023 Feb;
115:102523.
PMID: 36796283
No abstract available.
7.
Blay J, Palmerini E, Bollard J, Aguiar S, Angel M, Araya B, et al.
Crit Rev Oncol Hematol
. 2022 Oct;
180:103827.
PMID: 36220678
No abstract available.
8.
Blay J, Palmerini E, Bollard J, Aguiar S, Angel M, Araya B, et al.
Crit Rev Oncol Hematol
. 2022 Apr;
174:103685.
PMID: 35460913
Bone sarcoma are infrequent diseases, representing < 0.2% of all adult neoplasms. A multidisciplinary management within reference centers for sarcoma, with discussion of the diagnostic and therapeutic strategies within an...
9.
Palassini E, Mir O, Grignani G, Vincenzi B, Gelderblom H, Sebio A, et al.
Breast Cancer Res Treat
. 2022 Feb;
192(3):603-610.
PMID: 35150367
Background: We aimed at investigating outcome of systemic treatments in advanced breast PT. Methods: All cases of advanced breast PT treated with systemic treatments from 1999 to 2019, in one...
10.
Blay J, Hindi N, Bollard J, Aguiar Jr S, Angel M, Araya B, et al.
Cancer Treat Rev
. 2021 Nov;
102:102312.
PMID: 34798363
No abstract available.